SPECIALIZED EXAMS CARRIED OUT AT ANTOINE LACASSAGNE CENTER

BY THE LABORATORY DIVISION

The Laboratories Department at Lacassagne was set up in September 2012 and is made up of practitioners (doctors, specialists, biologists) and specialized medical and technical personnel. The Laboratories Department collaborates closely with the various care units and plays an essential role in the care chain. It includes the Oncopharmacology Laboratory, the Anatomy and Pathology Cytology Unit and the Sample Depot.

Specialized examinations performed at the Oncopharmacology Laboratory
The objective of the Oncopharmacology laboratory is to optimize medication management through a personalized medicine approach that enables the cancer treatment to be oriented in accordance with the specific individual characteristics of the patient’s tumor (search for tumor mutations, etc.), or in relation to the patient (genetic characteristics intrinsic to the patient). The goal is to adapt the treatment to each patient in order to administer the right treatment at the right dose. In this context, the laboratory carries out both a hospital activity, and a translational research activity.

The activity of the Oncopharmacology laboratory is multiple. The analyzes carried out as well as the methods for taking, storing and transporting biological samples are detailed in our Oncopharmacology analysis guide.

Request forms for the corresponding analyzes are available on the following links:

Contacts
Gérard Milano, PhD, Laboratory Manager
Marie-Christine Etienne-Grimaldi, Biological Pharmacist, Quality Manager of the Laboratories Unit
Telephone 04 92 03 15 55 (secretariat), Fax 04 93 81 71 31

Analysis of tumor characteristics from tumor biopsies

The laboratory performs blood sample analyzes (phenotyping and genotyping) to identify constitutional (inherited) enzyme deficits that can lead to severe toxicities when molecules with pharmacokineticswhich are controlled by these enzymes are administered. These analyzes make it possible to objectively guide the dosage of fluoropyrimidines (deficiency of dihydropyrimidine dehydrogenase, DPD) and irinotecan (deficit of uridine diphosphate glucuronosyltransferase 1A1, UGT1A1). In this context, the Laboratory of Oncopharmacology was approved in July 2001 by the Ministry of Employment and Solidarity (Regional Directorate of Sanitary and Social Affairs of Provence-Alpes-Côte d’Azur) for carrying out examinations of genetics applied to pharmacogenetics. Two accredited laboratory practitioners carry out these analyzes.

Analysis of drugs at the blood level

The laboratory also has a pharmacokinetic role which consists of measuring the blood concentrations of the molecule of interest in order to individually adjust the dose of the drug, so as to target concentrations with the best efficacy / toxicity ratio.

BY THE NUCLEAR MEDICINE SERVICE

The Nuclear Medicine Department is part of the Inter-Hospital Medical Federation CHU / CAL of Nuclear Medicine. As part of a university hospital, many of its practitioners have teaching and research roles. The teaching concerns in particular that of Biophysics to first year medical students. The research activity is backed by a research unit accredited by the CEA and the university (UMR 4320) composed of around fifteen researchers, located at the Faculty of Medicine.

The Nuclear Medicine Department is part of the Inter-Hospital Medical Federation CHU / CAL of Nuclear Medicine. As part of a university hospital, many of its practitioners have teaching and research roles. The teaching concerns in particular that of Biophysics to first year medical students. The research activity is backed by a research unit accredited by the CEA and the university (UMR 4320) composed of around fifteen researchers, located at the Faculty of Medicine.

The department is the only one to carry out iodine-131 treatments for thyroid diseases. It participates in local thyroid CPR for the management of usual thyroid cancers as well as in national TUTHYREF CPRs for iodine 131 resistant tumors.

The service has scintigraphic cameras coupled to CT scanners in order to perform all the usual scans in hybrid imaging (coupled with scanner imaging).
Positron Emission Tomography (PET) equipment is the latest generation and allows for scanner-assisted CT acquisitions with contrast product injection.
The Lacassagne PET installation is the only one in the department to be accredited by the European organization EARL / EANM.

This accreditation validates the quality of patient care for PET imaging in oncology and is requested in particular by the European Organization for Research and Treatment of Cancer (EORTC) for participation in international clinical trials in oncology.

The facility also has the national “Memento” qualification, which validates the quality of neurology examinations. This enables patients to benefit from early detection of Alzheimer’s disease in collaboration with the Center’s Memory Resource and Research Center, Nice University Hospital as part of the Alzheimer’s plan.
This facility also aims to develop new imaging techniques, particularly the use of new radiopharmaceuticals. It is currently possible to use Fluoro-Choline (for the evaluation of prostate cancer patients) and Fluoro-Dopa (for the evaluation of certain neuro-endocrine tumors, for brain tumors and for the diagnosis of parkinsonian syndromes).

The service is the promoter of a multicentric Hospital Clinical Research Program called POSEIDON (Positron Emission Imaging using 18f-fDOpa in Neurooncology).